Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.68 |
| ▸ | KDR | P35968 | 6/20 | 0.68 |
| ▸ | RET | P07949 | 4/20 | 0.68 |
| ▸ | JAK2 | O60674 | 2/20 | 0.68 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.68 |
| ▸ | CDK1 | P06493 | 2/20 | 0.68 |
| ▸ | ROS1 | P08922 | 2/20 | 0.68 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.68 |
| ▸ | CDK2 | P24941 | 2/20 | 0.68 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.68 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.68 |
| ▸ | CLK2 | P49760 | 2/20 | 0.68 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.68 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.68 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.68 |
| ▸ | CDC7 | O00311 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24096480 | 0.87 | JAK2 (0.86) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL19732801 | 0.87 | SRC (0.68) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL1318717 | 0.85 | SRC (0.77) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL401336 | 0.85 | KDR (0.77) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL18539078 | 0.84 | SRC (0.76) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL5805110 | 0.84 | RET (0.64) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL23847456 | 0.83 | KDR (0.75) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL4825086 | 0.83 | LCK (0.70) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL4826075 | 0.82 | KDR (0.78) | SRCKDRRETJAK2DYRK3 | |
| SCHEMBL4826083 | 0.82 | KDR (0.78) | SRCKDRRETJAK2DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-10981920-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| CN-108026101-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-28 | — | — | US | disclosed |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
| US-10179788-B2 | — | RET, GFRA1, GFRA2 | SRC 146/4885KDR 709/4885RET 1/4885 |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
| US-10981920-B2 | — | RET, GFRA1, GFRA2 | SRC 146/4885KDR 709/4885RET 1/4885 |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | SRC 153/4885KDR 847/4885RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.